Lipid Nanoparticle mRNA Delivery for Sustained Protein Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional gene therapy using DNA for protein replacement in diseases like Fabry disease is limited by integration into the host genome, potential mutations, immune responses, and difficulty in achieving sustained therapeutic protein levels, while mRNA therapy faces instability and low translation levels.
Innovation Solution
Lipid nanoparticle compositions deliver stabilized mRNA encoding secreted proteins to target cells, acting as a depot for sustained production of therapeutic levels of functional proteins, overcoming the limitations of DNA-based therapies by avoiding genomic integration and enhancing protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If DNA is used for gene therapy to achieve sustained protein production, then long-lasting action is obtained, but integration into host genome may cause mutations and immune responses
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary delivery system to transport mRNA into cells. This mediator enables sustained protein production without requiring DNA integration into the host genome, thereby achieving the duration benefit while avoiding the harmful integration effects. The lipid nanoparticle protects the mRNA and facilitates its cellular uptake and sustained expression.
2Object-affected harmful factors
If mRNA is used for gene therapy to avoid genomic integration, then safety is improved, but protein production levels are insufficient
Solution Approach 1:
The patent modifies the mRNA molecule itself by incorporating specific sequence elements (such as 5' cap structures, 3' poly-A tails, and optimized coding sequences) that enhance its stability and translation efficiency. These parameter changes to the mRNA structure enable it to achieve therapeutic protein production levels while maintaining the safety advantages of non-integrating delivery.
Solution Approach 2:
The patent creates a composite delivery system combining mRNA with lipid nanoparticles. This composite structure protects the mRNA from degradation, enhances cellular uptake, and improves protein production efficiency while maintaining the non-integrating safety profile of mRNA therapy.
3Reliability
If conventional gene therapy is used for protein replacement, then therapeutic effect is achieved, but achieving sustained therapeutic levels is difficult
Solution Approach 1:
The patent performs preliminary optimization of the mRNA sequence and structure before delivery, including adding stabilizing elements and optimization sequences that pre-establish the conditions for sustained expression. This preliminary action ensures that once the mRNA is delivered, it can maintain therapeutic protein levels for extended periods without requiring repeated dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions achieve sustained, therapeutic levels of secreted proteins, exceeding normal physiological levels and maintaining expression for extended periods, providing effective treatment for protein deficiencies such as lysosomal storage disorders.
Implementation Method 1
Lipid nanoparticle compositions deliver stabilized mRNA encoding secreted proteins to target cells
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.